Journals in Hematology

1-10 of 36 results in All results

Atherosclerosis

• ISSN: 0021-9150
• 5 Year impact factor: 5.3
• Impact factor: 4.9

Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors, and clinical manifestations. Atherosclerosis covers basic and translational clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors which include: disturbances of lipid and lipoprotein metabolism, diabetesand hypertension, thrombosis, and inflammation. Atherosclerosis particularly welcomes original or review papers regarding the pathogenesis, the environmental, genetic, and epigenetic basis, and the diagnosis, treatment, and risk factors of atherosclerosis and related diseases.Complimentary online access is available to all members of the European Atherosclerosis Society. A reduced personal subscription rate is available to all members of the International Atherosclerosis Society.

Subscribe

Best Practice & Research Clinical Haematology

• ISSN: 1521-6926
• 5 Year impact factor: 2.3
• Impact factor: 2.2

Best Practice & Research Clinical Haematology provides a comprehensive review of current clinical practice and thinking within the specialty of haematology.All chapters are commissioned and written by an international team of practicing clinicians with the Guest Editors for each issue drawn from a pool of renowned experts and opinion leaders.All chapters take the form of practical, evidence-based reviews that seek to address key clinical issues of diagnosis, treatment and patient management.Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. Management will be described in practical terms so that it can be applied to the individual patient.Boxed and bulleted Learning Objectives and Practice Points are features within each chapter and will highlight the core and essential knowledge that will help the physician to provide the best care to their patients.

Subscribe

Biochimica et Biophysica Acta: Proteins and Proteomics

• ISSN: 1570-9639
• 5 Year impact factor: 2.8
• Impact factor: 2.5

BBA Proteins and Proteomics covers protein structure conformation and dynamics; protein folding; protein-ligand interactions; enzyme mechanisms, models and kinetics; protein physical properties and spectroscopy; and proteomics and bioinformatics analyses of protein structure, protein function, or protein regulation.The journal no longer considers manuscripts dealing with binding of compounds such as drugs or drug analogues to circulatory proteins such as serum albumin. These studies are better accommodated in journals dealing with drug design and development.Manuscripts must advance our insights into the molecular and mechanistic properties of proteins. Computational studies must generally be validated or complemented by experimental studies. Studies only consisting of computational work will not be considered unless they provide new theoretical insight that allows us to better understand or reinterpret surprising or unexpected experimental data.Comparative proteomics studies are generally not considered for review unless they provide specific insights into the structural and/or functional properties of individual proteins. Proteomics studies must also address properties of individual proteins and should as far as possible be validated by direct investigations of relevant identified proteins.Concise and comprehensive reviews of recent developments are considered for publication. However, authors are strongly advised to consult one of the Executive Editors before starting a review.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Subscribe

Blood

• ISSN: 0006-4971
• 5 Year impact factor: 19.2
• Impact factor: 21

Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well-organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to submit a presubmission inquiry if they are uncertain whether their work falls within the general scope of the journal.Blood has formulated more precise scopes for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and clinical trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.Immunobiology and Immunotherapy scopeVascular Biology scopeHIV/HTLV scopeClinical Trials scopeBlood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.Papers felt to be outside the scope of Blood will be returned to the author without full peer review.

Subscribe

Blood Cells, Molecules and Diseases

• ISSN: 1079-9796
• 5 Year impact factor: 2.2
• Impact factor: 2.1

BCMD is interested in contributions in basic, translational and clinical research focusing on the biology of blood cells and the pathophysiology of blood disorders, with a specific interest in non-malignant conditions.We will consider studies on hematological malignancies when secondary to inherited or acquired bone marrow failure or disorders of the immune system.Research Areas include:Erythropoiesis, Erythrocyte Biology, Hemoglobin and its disordersMyelopoiesis, myeloid cells and disorders of the myeloid lineage (incl. myeloproliferative disorders)Megakaryopoiesis and platelet disordersHemostasis & Thrombosis and disorders of coagulationTransfusion medicine and the study of therapeutic blood products (including novel biotechnologies related to transfusion products)Bone marrow failure (severe aplastic anemia, myelodysplasia, etc.)Immunodeficiency and dysregulation of the immune systemAuto-immune disorders relating to blood

Subscribe

Blood Reviews

• ISSN: 0268-960X
• 5 Year impact factor: 7.7
• Impact factor: 6.9

This respected international journal, Blood Reviews, is a vital information resource, bringing together appraisals of clinical practice, and research from recognized experts. Specially commissioned peer reviewed articles from leading researchers and practitioners guarantee truly global coverage of all the sub-specialties of hematology.Blood Reviews publishes review articles covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editors welcome suggestions from potential authors. They should first write a brief outline of an intended review along with their publication record on topic and send this to Dr Drew Provan ([email protected]) or to Dr Hillard Lazarus ([email protected]). All articles are subject to peer review. Author queries can also be sent to the Blood Reviews editorial office [email protected]

Subscribe

Cancer Epidemiology

• ISSN: 1877-7821
• 5 Year impact factor: 2.7
• Impact factor: 2.4

Cancer determinants, prevention, prognosis and outcomesCancer Epidemiology publishes original research, prioritizing studies that contribute new information about cancer causes, prevention and control. As such, the journal's scope covers all aspects of cancer epidemiology including studies of:• Risk factors for cancer initiation, development, and prognosis • Early detection, prevention, and screening • Survivorship • Descriptive patterns and trends • MethodologyCancer Epidemiology welcomes original articles, reviews (systematic and critical), meta-analyses, invited editorials and commentaries, as well as letters to the editor commenting on research previously published in the journal.Cancer Epidemiology (Cancer Epidemiol.) is indexed and abstracted in: MEDLINE/PubMed, Current Contents/Clinical Medicine, the Science Citation Index Expanded, and Thomson Reuters Journal Citation Reports (Science Edition).

Subscribe

Cancer Genetics

• ISSN: 2210-7762
• 5 Year impact factor: 1.7
• Impact factor: 1.4

The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support CenterCancer Genetics is proud to be affiliated with the Cancer Genomics Consortium.

Subscribe

Cancer Letters

• ISSN: 0304-3835
• 5 Year impact factor: 8.3
• Impact factor: 9.1

An international journal providing a forum for original and pertinent contributions in cancer researchCancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and translational oncology. Additionally, Special Issues highlight topical areas in cancer research. Basic areas of interest to a broad readership of Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine, including metronomic chemotherapy.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: https://service.elsevier.com.

Subscribe

Cancer Treatment Reviews

• ISSN: 0305-7372
• 5 Year impact factor: 10.9
• Impact factor: 9.6

Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support CenterJournal of Cancer Treatment Reviews' Inclusion and Diversity PledgeThis journal pledges to maintain diversity on the editorial team. This sits within Elsevier's broader ongoing inclusion & diversity efforts. Equity and inclusion in publishing is critically important for scientific excellence and innovation. We believe passionately in the power of an inclusive publishing environment, not only to do what is right, but to enrich, strengthen and advance us all.

Subscribe